Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis

Clinical Genitourinary Cancer

Volumn 15, Issue 1, 2017, Pages 23-30.e2

  Necchi, Andrea ^a   Pond, Gregory R ^b   Raggi, Daniele ^a   Giannatempo, Patrizia ^a   Vogelzang, Nicholas J ^c   Grivas, Petros ^d   Galsky, Matthew D ^e   Bellmunt, Joaquim ^f   Sonpavde, Guru ^g  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

First line therapy; Meta analysis; Systemic therapy; Taxanes; Urothelial carcinoma

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; TAXOID;

ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; METASTASIS; MULTIVARIATE ANALYSIS; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL (TOPIC); SURVIVAL ANALYSIS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 85008213277     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.05.003     Document Type: Review

References (46)

1. 1 Abida, W., Bajorin, D.F., Rosenberg, J.E., First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. Hematol Oncol Clin North Am 29 (2015), 319–328.
2. 2 von der Maase, H., Hansen, S.W., Roberts, J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000), 3068–3077.
3. 3 Bellmunt, J., von der Maase, H., Mead, G.M., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study 30987. J Clin Oncol 30 (2012), 1107–1113.
4. 4 Giannatempo, P., Pond, G.R., Sonpavde, G., et al. The impact of adding taxanes to gemcitabine and platinum chemotherapy for the first-line therapy of advanced or metastatic urothelial cancer: a systematic review and meta-analysis. Eur Urol 69 (2016), 624–633.
5. 5 Sonpavde, G., Watson, D., Tourtellot, M., et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer 10 (2012), 1–5.
6. 6 Galsky, M.D., Hahn, N.M., Rosenberg, J.E., et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 29 (2011), 2432–2438.
7. 7 Galsky, M.D., Chen, G.J., Oh, W.K., et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23 (2012), 406–410.
8. 8 Dreicer, R., Manola, J., Roth, B.J., et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100 (2004), 1639–1645.
9. 9 Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100.
10. 10 Carles, J., Nogué, M., Domènech, M., et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59 (2000), 24–27.
11. 11 Bellmunt, J., de Wit, R., Albanell, J., Baselga, J., A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. Eur J Cancer 37 (2001), 2212–2215.
12. 12 Shannon, C., Crombie, C., Brooks, A., et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 12 (2001), 947–952.
13. 13 Nogué-Aliguer, M., Carles, J., Arrivi, A., et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97 (2003), 180–186.
14. 14 Linardou, H., Aravantinos, G., Efstathiou, E., et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology 64 (2004), 479–484.
15. 15 Hoschke, B., May, M., Seehafer, M., Helke, C., Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium. Int J Urol 11 (2004), 461–466.
16. 16 Bamias, A., Moulopoulos, L.A., Koutras, A., et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer 106 (2006), 297–303.
17. 17 Xu, N., Zhang, X.C., Xiong, J.P., et al. A phase II trial of gemcitabine plus cisplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer, 7, 2007, 98.
18. 18 Dogliotti, L., Cartenì, G., Siena, S., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52 (2007), 134–141.
19. 19 Bamias, A., Lainakis, G., Kastritis, E., et al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology 73 (2007), 290–297.
20. 20 Hudson, E., Lester, J.F., Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single-centre experience and review of the literature. Eur J Cancer Care 19 (2010), 324–328.
21. 21 Baitar, A., De Vos, M., Vandebroeck, A., Schrijvers, D., Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: a phase II study. J Ger Oncol 2 (2011), 31–35.
22. 22 De Santis, M., Bellmunt, J., Mead, G., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30 (2012), 191–199.
23. 23 Park, J.H., Lee, S.W., Kim, H.S., et al. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 71 (2013), 1033–1039.
24. 24 Meluch, A.A., Greco, F.A., Burris, H.A., et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19 (2001), 3018–3024.
25. 25 Friedland, D., Gregurich, M.A., Belt, R., et al. Phase II evaluation of docetaxel plus gemcitabine in patients with advanced unresectable urothelial cancer. Proc Am Soc Clin Oncol, 21, 2002, 153b (abstract 2427).
26. 26 Garcia-Del-Muro, X., Marcuello, E., Mellado, B., et al. Phase II multicenter study of docetaxel plus gemcitabine as first-line treatment in advanced urothelial cancer. Proc Am Soc Clin Oncol, 22, 2003, 409 (abstract 1643).
27. 27 Gitliz, B.J., Baker, C., Chapman, Y., et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98 (2003), 1863–1869.
28. 28 Kaufman, D.S., Carducci, M.A., Kuzel, T.M., et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22 (2004), 393–397.
29. 29 Ardavanis, A., Tryfonopoulos, D., Alexopoulos, A., Kandylis, C., Lainakis, G., Rigatos, G., Gemcitabine and docetaxel as first-line treatment for advanced urothelial caercinoma: a phase II study. Br J Cancer 92 (2005), 645–650.
30. 30 Li, J., Juliar, B., Yiannoutsos, C., et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 23 (2005), 1185–1191.
31. 31 Srinivas, S., Guardino, A.E., A nonplatinum combination in metastatic transitional cell carcinoma. Am J Clin Oncol 28 (2005), 114–118.
32. 32 Dumez, H., Martens, M., Selleslach, J., et al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anticancer Drugs 18 (2007), 211–218.
33. 33 Neri, B., Vannini, L., Giordano, C., et al. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18 (2007), 1207–1211.
34. 34 Calabrò, F., Lorusso, V., Rosati, G., et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 115 (2009), 2652–2659.
35. 35 Raghavan, D., Tangen, C.M., Moinpour, C., et al. Paclitaxel gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028. J Clin Oncol, 28(15 Suppl 1), 2010.
36. 36 Matsui, Y., Nishiyama, H., Yoshimura, K., et al. The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers. Int J Clin Oncol 18 (2013), 321–328.
37. 37 Ko, Y.J., Canil, C.M., Mukherjee, S.D., et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 14 (2013), 769–776.
38. 38 Goldstein, D., El-Maraghi, R.H., Hammel, P., et al. Nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst, 31, 2015, 107.
39. 39 Quinn, D.I., Ruel, N., Twardowski, P., et al. Eribulin in advanced urothelial cancer (AUC) patients (pts): a California Cancer Consortium trial – NCI/CTEP 7435. J Clin Oncol, 33(suppl), 2015 abstract 4504.
40. 40 Hoffman-Censits, J.H., Vaughn, D.J., Lin, J., et al. A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy. J Clin Oncol, 32(suppl), 2014 abstract e15519.
41. 41 Sonpavde, G., Galsky, M.D., Vogelzang, N.J., First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?. J Clin Oncol 28 (2010), e441–e442.
42. 42 Plimack, E.R., Bellmunt, J., Gupta, S., et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol, 33(suppl), 2015 abstract 4502.
43. 43 Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
44. 44 Petrylak, D.P., Powles, T., Bellmunt, J., et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol, 33(suppl), 2015 abstract 4501.
45. 45 Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
46. 46 Sonpavde, G., Pond, G.R., Di Lorenzo, G., et al. Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC). J Clin Oncol, 34(suppl 2S), 2016 abstract 386.